Top Markets
#1 Derive Derive +32.37%
#2 Cross Cross +15.42%
#3 Glidr Glidr +10.10%
#4 Gama Token Gama Token +9.10%
#5 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +6.92%
#6 Palladium Network Palladium Network +6.09%
#7 Based Based +5.99%
#8 Geodnet Geodnet +5.11%
#9 龙虾 (Lobster) 龙虾 (Lobster) +5.09%
#10 Talus Network Talus Network +4.83%
Coin of the day
Derive Derive
Settings
Language
ENGLISH
Currency
USD
Theme
Guard Therapeutics International AB (publ) Guard Therapeutics International AB (publ)

Guard Therapeutics International AB (publ)

GUARD
Rank in Stocks #36113
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company... Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Share Price
$0.14966934
Last synced: 2026-08-14
Market Cap
$3.02M
Change (1 day)
3.72%
Change (1 year)
-93.70%
Country
SE
Trade Guard Therapeutics International AB (publ) (GUARD)

Category

Healthcare
Revenue for Guard Therapeutics International AB (publ) (GUARD)
Revenue in Aug 2026 TTM: 0
According to Guard Therapeutics International AB (publ) latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Guard Therapeutics International AB (publ) from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE